NANOGEN | Solution for infusion Glucose (as glucose monohydrate) 30% (w/v)

NANOGEN | Solution for infusion Glucose (as glucose monohydrate) 30% (w/v)

NANOGEN | Solution for infusion Glucose (as glucose monohydrate) 30% (w/v)

NANOGEN | Solution for infusion Glucose (as glucose monohydrate) 30% (w/v)

NANOGEN | Solution for infusion Glucose (as glucose monohydrate) 30% (w/v)

GLUCOSE 30%

GLUCOSE 30%

COMPOSITION
Glucose (as glucose monohydrate) 30% (w/v)
PHARMACEUTICAL FORM
Solution for infusion
A Clear, colourless solution, maybe not more than faintly yellow, no strange particles, packed in a colourless plastic bottle, sealed with plastic cap with two rubber discs inside.
Pharmacotherapeutic group: Carbohydrate solutions for parenteral nutrition, carbohydrates
ATC code: B05BA03
INDICATION
Glucose 30% indicated as a source of calories for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.
CONTRAINDICATION
The use of Glucose Intravenous Infusion 30% is contraindicated in patients: 
  • Who are severely dehydrated as hypertonic glucose solution can worsen the patient’s hyperosmolar state.
  • With known hypersensitivity to Glucose (see section Special Warnings and Precautions for use).
PHARMACODYNAMIC PROPERTIES
Mechanism of action
Glucose is metabolized ubiquitously as the natural substrate of the cells of the body. Under physiological conditions glucose is the most important energy supplying carbohydrate with a caloric value of approx. 17 kJ/g or 4 kcal/g. Neural tissue, erythrocytes and the medulla of the kidneys are amongst the tissues with an obligate requirement for glucose.
Pharmacodynamic effects
Glucose serves to maintain the blood glucose level and for the synthesis of important body components. It serves for the synthesis of glycogen, the storage form of carbohydrates. Primarily insulin, glucagon, gluco-corticosteroids and catecholamines are involved in the regulation of the blood glucose concentration.
PHARMACOKINETIC PROPERTIES
Absorption
Bioavailability: Since the solution is administered intravenously, its bioavailability is 100%. 
Distribution
On infusion glucose is first distributed in the intravascular space and is then taken up into the intracellular space. In adults, the concentration of glucose in the blood is 60 – 100 mg/100 mL, or 3.3 - 5.6 mmol/L (fasting).
Biotransformation
In glycolysis, glucose is metabolized to pyruvate. Under aerobic conditions pyruvate is completely oxidized to carbon dioxide and water. In case of hypoxia pyruvate is converted to lactate. Lactate can be partially re-introduced into the glucose metabolism (Cori cycle).
Elimination
The final products of the complete oxidation of glucose are eliminated via the lungs (carbon dioxide) and the kidneys (water).
STORAGE, SHELF LIFE, PACKING UNITS
Storage: In a cool and dry place at temperatures not exceeding 30oC, protect from light.
Shelf life: 3 years from manufacturing date.
Packing units:
12 plastic bottles of 500 mL per carton
24 plastic bottles of 250 mL per carton

 

Related products

Current product

PACEPHENE

Upcoming product

MOCIN

Current product

GLUCONA